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Abstract
We report on the process of post mortem
evaluation and genetic testing following the
death of a 25-year-old man due to ascending
aortic dissection leading to aortic rupture.
Following the negative clinical testing of a 12-
gene thoracic aortic aneurysm and dissection
panel, research testing revealed a novel
c.5732A>T (p.E1911V) variant in exon 34 of
the MYLK gene (NM_053025). Two likely path-
ogenic variants in this gene have been report-
ed previously in individuals with familial tho-
racic aortic aneurysm and dissection. Given
the unclear clinical consequence of the variant
found in our proband, we have classified this
change as a variant of uncertain significance.
In addition to discussing the complexity
involved in variant interpretation, we recog-
nize the need for additional research for more
accurate MYLK interpretation. Finally, we com-
ment on the unique challenges of post mortem
genetic testing. 
Introduction
Every year, approximately 30,000 deaths in
the United States alone are attributed to tho-
racic aortic dissection and rupture,1 which
despite being a common cause of mortality,
often remains undiagnosed until dissection or
death occurs.2 The annual reported incidence
of aortic dissection ranges from 2.5/100,0003 to
as high as 9.1/100,000 and 16.3/100,000 in
women and men, respectively.2 The true inci-
dence is difficult to determine due to frequent
misdiagnosis at the time of death.1 The major-
ity of individuals with thoracic aortic dissec-
tion (approximately 93%) are over the age of
40, with a mean age of 63 years.3 Of the indi-
viduals with thoracic aortic aneurysm and dis-
section (TAAD), some are identified to have an
underlying genetic syndrome. Disorders such
as Marfan, Loeys-Dietz, Ehlers-Danlos, and
Turner syndromes all predispose individuals to
medial degeneration of the aorta.2 Current
data suggest nearly 20% of individuals with
TAAD who are otherwise physically normal and
without an identified genetic syndrome have
at least one first-degree relative with TAAD.3
These 20% of individuals are designated to
have familial thoracic aortic aneurysm and dis-
section (FTAAD).3
Advances during recent decades have provid-
ed insights into the genetic etiology of both syn-
dromic forms of TAAD and nonsyndromic
FTAAD. Currently, genetic testing identifies a
molecular cause in about 20% of individuals
with FTAAD, with the majority of genes identi-
fied encoding for smooth muscle cell proteins.4
Pathogenic changes in ACTA2 account for
approximately 14% of all FTAAD cases.4
However, additional genes have been proposed
to cause FTAAD. In 2010, Wang et al. reported
two variants in the MYLK gene as likely patho-
genic given the predicted damaging effects and
the segregation within the families.5 Although
transcribed in all tissues, MYLK is mostly
expressed in smooth muscle.6 MYLK encodes
for the myosin light chain kinase (MLCK)
enzyme, which plays a crucial role in smooth
muscle cell contraction.6 Once bound to a
Ca2+/calmodulin complex, MLCK becomes acti-
vated and is able to phosphorylate its target pro-
tein, the regulatory light chain of myosin II.6
Little is known about the potential role of MYLK
variants in aortopathy. The sentinel report by
Wang et al. in 2010 represents the first and only
publication involving MYLK variants in FTAAD
subjects.5 Currently, nine MYLK variants are
listed in the ClinVar database.7 Of these nine
variants, six are germline variants, and four of
these six are reported in association with TAAD
(Table 1).7 Of note, the p.Arg1480Ter and the
p.Ser1759Pro variants are listed from the article
published by Wang et al.5
Here we report the case of a 25-year old man
who died unexpectedly due to an ascending
aortic dissection and rupture. Genetic counsel-
ing and testing were performed following his
death. Comprehensive next generation
sequencing (NGS) analysis using a pan cardio-
vascular panel including 246 genes has identi-
fied a novel c.5732A>T (p.E1911V) variant in
exon 34 of the MYLK gene (NM_053025),
which we classified as a variant of uncertain
significance. In addition to reporting the post
mortem assessment, we describe some of the
difficulties and limitations associated with
post mortem genetic testing and counseling,
and the complexity of aortopathy genetic eval-
uation.  
Materials and MethodsClinical phenotype
The proband was a 25-year old Caucasian
male with a history of morbid obesity and
hypertension, initially evaluated at an outside
institution. He was 195.6 cm tall and weighed
155.9 kg. According to maternal report, previ-
ous medical history includes suspected subaor-
tic stenosis at age 12; however, echocardio-
gram imaging at age 19 was normal. He had no
further cardiologic evaluations at his local
institution until the time of his death. He vis-
ited the emergency department of a third hos-
pital four days prior to his death with com-
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plaints of back and abdominal pain, shortness
of breath, and diarrhea. A computed tomogra-
phy scan of the abdomen and pelvis was nor-
mal with the exception of an umbilical hernia
and an atrophic right kidney. He was dis-
charged from the emergency department with
a diagnosis of gastroenteritis. Four days later,
he returned to the emergency department
given his persistent symptoms. An electrocar-
diogram indicated severe diffuse ST elevation
of all leads except aVR, III, and aVF, and PR
depression in lead II. During a cardiology con-
sultation, the patient became short of breath,
diaphoretic, cyanotic and pulseless.
Resuscitation was attempted for an extended
period of time and other than one episode of
ventricular fibrillation, he had no cardiac elec-
trical activity. Transthoracic ultrasound at the
bedside revealed pericardial effusion. On
autopsy, he was found to have a ruptured type
A aortic dissection from the aortic valve to the
abdominal aorta. Additionally, he had dilata-
tion and mild hypertrophy of the left ventricle,
a sign of long-standing hypertension. The
pathology report showed aortic wall changes
consistent with medial degeneration. The
coroner noted that there was no evidence of
coarctation of the aorta. No further details
regarding the size or changes of the aorta were
provided. Toxicology analyses on both blood
and urine were negative. 
Additional medical history was noncontribu-
tory. Although no dysmorphologic examination
was obtained, in a photograph of the patient,
he did not appear to have physical characteris-
tics consistent with a dysmorphic syndrome. Family history
A three-generation pedigree was obtained
during the genetic counseling session at an
Indiana University Health facility with the
proband’s mother and father (Figure 1). The
proband has a living brother and sister, both of
whom had normal screening echocardiograms
following their brother’s death. The brother
was found to have mild left ventricular hyper-
trophy of 12 mm. He had two ventricular septal
defects at birth, which subsequently closed. 
The proband’s mother reported she had a
previous echocardiogram suggestive of mitral
valve prolapse with regurgitation; however, fol-
low-up echocardiograms were normal. Most
recently, both an electrocardiogram and an
echocardiogram were normal. The mother also
self-reported additional physical features,
including mild scoliosis, arachnodactyly, mild
pectus excavatum, and mild myopia. She had
no other ocular abnormalities, skin laxity,
excessive bruising, hypermobility, or
smooth/velvety skin. Of note, no individuals in
the family received a formal evaluation at their
institution to rule out the presence of a con-
nective tissue disorder, though the index of
suspicion was low after cardiologist and genet-
ic counselor visits. Very little information is
known about the more distant maternal rela-
tives. The maternal family is of Scottish and
English ancestry.
By echocardiogram, the proband’s father
had mild enlargement of the sinuses of
Valsalva (4.26 cm), normal sinutubular junc-
tion (3.5 cm), and normal ascending aorta
diameter (3.95 cm). He also had stage 1 dias-
tolic dysfunction, mild right ventricular
enlargement, and was borderline tachycardic.
An echocardiogram approximately one year
later also showed mild dilation at the sinuses
of Valsalva (4.1 cm) and ascending aorta (3.8
cm), a small left ventricular cavity, mild con-
centric left ventricular hypertrophy, and stage
1 to 2 left ventricular diastolic dysfunction. No
z-score measurements were calculated in the
reports. He is currently taking metformin for
type II diabetes mellitus and a prophylactic
statin medication and lisinopril for further vas-
cular complications. Additional medical history
includes morbid obesity and obstructive sleep
apnea. Paternal family history is significant for
a paternal grandfather with an abdominal aor-
tic aneurysm detected at age 75. He also has a
history of heavy tobacco use, uncontrolled
hypertension, and a myocardial infarction at
77 years of age. The paternal family is of
German, Irish, and Swiss ancestry. Molecular analysis
Following the patient’s death we were able
to obtain a frozen blood specimen collected in
two red top tubes containing NaF and EDTA.
We were able to successfully extract sufficient
DNA for subsequent genetic analysis.
Following informed consent by the proband’s
parents, a 12-gene clinical TAAD panel was
performed. The test included sequencing of
ACTA2, CBS, COL3A1, COL5A1, COL5A2, FBN1,
FBN2, MYH11, SLC2A10, SMAD3, TGFBR1, and
TGFBR2. In addition, research-based molecu-
lar analysis was performed on the proband,
using custom HaloPlex Target Enrichment
System (Agilent Technologies, Santa Clara,
CA, USA) to capture the coding sequence and
intron/exon boundaries of 246 cardiovascular
related genes. Targeted regions found to have
corresponding pseudogenes elsewhere in the
genome were excluded. The total sequence-
able design size obtained was of 2.37 Mbp and
the recommended minimum sequencing per
sample was of 474 Mbp for 200x sequencing
coverage depth. Enrichment was validated and
target DNA concentration of 175-625 bp size
products was determined using the Agilent
2200 TapeStation, while the library was
reassessed with the 2200 TapeStation.
Approximately 3 pM of pooled libraries spiked
with 5% of 12.5 pM PhiX library (Illumina, Inc.,
San Diego, CA, USA) were loaded onto an
Illumina MiSeq using a standard reagent kit v2
(300 cycles) and standard flow cell. FASTQ files
were obtained from the MiSeq instrument for
each run. Adapter sequences and low quality
bases (trim from the 3’ end) were trimmed
from the 150 bp pair-end MiSeq reads using
Trim Galore (v0.3.2). The resulting reads were
mapped to the human reference genome UCSC
build hg19 using BWA version 0.7.5a8 and
SAMtools version 0.1.19.9 The aligned reads
were further realigned and the quality scores
were recalibrated using GATK 2.8-1.10 Variants
were called using GATK Unified Genotyper
restricted to specified target regions. Variants
were annotated using ANNOVAR11 and the
Human Gene Mutation Database (HGMD
Professional 2014.2, BIOBASE, Beverly, MA,
http://www.hgmd.org/).12,13 A final report of
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Figure 1. Three-generation pedigree with most recent cardiac imaging. 
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variants was generated for the targeted gene
regions. The report consists of variant map-
ping information, gene annotation, amino acid
change annotation, variant functional annota-
tion (SIFT, PolyPhen, LRTs, and Mutation
Taster), variant evolutionary conservation
annotation (PhyloP and GERP++), variant
presence and allele frequencies in currently
publicly sequenced populations (dbSNP identi-
fiers, 1000 Genomes Project allele, NHLBI-ESP
6500 exome project), and known disease-relat-
ed functional annotation from HGMD. The var-
ious annotation using the aforementioned pre-
diction software provide a cumulative damage
score ranging from 0 (no damage) to 6 (high-
est damage).
Results
Molecular findings
Clinical molecular analysis of the 12-gene
clinical TAAD panel was negative for any path-
ogenic variants. The testing did reveal a
c.5745G>C (p.E1915D) variant in MYH11,
which was reported as likely benign because
the amino acid change is conservative, in sili-
co models predict the change not to be damag-
ing, the residue is not conserved across
species, and no pathogenic variants have been
reported nearby the location of this variant.
The research NGS panel confirmed the pres-
ence of the MYH11 variant and identified a
novel c.5732A>T (p.E1911V) variant in exon 34
of the MYLK gene (NM_053025). Both variants
were confirmed by Sanger sequencing.
Analyses of the biological parents identified
the MYLK variant was paternally inherited. 
Discussion
Thoracic aortic aneurysm with dissection is
a devastating disease with a mortality rate of
nearly 97%.4 Unfortunately, for many families
sudden death is the first sign of disease,2 and
because of this, it is crucial each case is inves-
tigated thoroughly and appropriate genetic
assessment is offered in order to determine
the likelihood of a hereditary predisposition to
developing TAAD. In the previous sections we
have described the post mortem assessment of
a subject who died following aortic dissection.
However, there are several limitations that
should be discussed in depth when pursuing
genetic testing and interpreting genetic test
results.
The first issue we encountered was the lack
of adequate clinical and physical history. All
notes and results from clinical tests performed
prior to the post mortem evaluation were
obtained from a third institution, and we had
no available information about a potential his-
tory of joint hypermobility or skin hyperexten-
sibility. However, in the case presented here,
the autopsy analysis identified a ruptured type
A aortic dissection from the aortic valve to the
abdominal aorta. Other causes such as toxic
etiology or coarctation of the aorta were ruled
out by the coroner, warranting a genetic basis
to be considered in the differential diagnosis.
It is known that dissection can occur even
without prior aortic aneurysm.1 This was previ-
ously reported by Wang et al. in the individuals
with MYLK variants, where aortic dissection
occurred with little to no identified enlarge-
ment of the aorta.5 
A second issue to be considered was the
availability of adequate tissue specimen.
According to the National Association of
Medical Examiners, a sample adequate for
potential genetic testing should be saved from
any individual younger than 40 years of age
who dies suddenly and unexpectedly, when
there is suspicion of a genetic disease attribut-
ing to their death.14 Ideally, the sample should
be in the form of 5-10 mL of blood preserved in
a K2EDTA (purple top) tube.14 If a sample is
saved, next of kin should be informed and
proper consent and authorization must be
obtained prior to testing. In the present case,
our inquiry revealed two red top tubes of
frozen blood, which ultimately contained
extractable DNA. 
A third significant issue was the relatively
nonspecific family history. Although the pater-
nal family history appeared suspicious for aor-
tic disease, there were significant confound-
ing environmental factors. The proband’s
father presented with mild dilatation of the
aortic sinuses and ascending aorta; however,
his morbid obesity could be a contributing fac-
tor, provided that aortic size increases with
both age and body surface area.2 Similarly, the
paternal grandfather was diagnosed with an
isolated abdominal aortic aneurysm at age 75,
but has a history of heavy tobacco use and
uncontrolled hypertension, which are both
known risk factors for developing an aortic dis-
section.2 In general, individuals with disease of
the ascending aorta do not commonly have
family members with disease of the abdominal
aorta.1 In cases of isolated aortic aneurysm, it
is certainly possible that an underlying genetic
factor is contributing to the aneurysm in addi-
tion to environmental factors. Although our
proband’s mother reported some physical fea-
tures consistent with Marfan syndrome such
as scoliosis, arachnodactyly, mild pectus exca-
vatum, and myopia, she does not meet clinical
diagnostic criteria for Marfan syndrome.15
Further, the diagnosis appears unlikely given
her negative FBN1 genetic analysis.  
Finally, the present case raises questions on
proper interpretation of MYLK variants. In addi-
tion to assessing how a change would affect the
gene, the complexity in interpretation reflects
the fact that little is currently known about this
gene and its association with aortopathy. Other
than Wang et al.,5 no other publications have pro-
vided additional evidence supporting this associ-
ation. It is known that MLCK is an integral com-
ponent of the smooth muscle cell contractile
apparatus.6 Therefore, it is reasonable to support
the idea that deleterious mutations in MYLK
could contribute to aortic wall degeneration in a
manner similar to ACTA2 and MYH11
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Table 2. Next generation sequencing variant results after Sanger confirmation in genes associated with thoracic aortic aneurysm and
dissection.
Gene                 Accession number                 Exon            Nucleotide change              Amino acid change              Damage score (0-6)
MYH11                                   002474                                       40                              c.5745G>C                                      p.Glu1915Asp                                               2
MYLK                                     053025                                       34                              c.5732A>T                                       p.Glu1911Val                                                2
Table 1. Germline variants in MYLK reported in ClinVar.
Variant                        Clinical phenotype                          Suggested clinical significance
p.Gly1360Asp                       TAAD                                                                 Uncertain significance
p.Gly866Ser                         TAAD; disproportionate tall stature          Uncertain significance
p.Arg1480Ter                       TAAD                                                                 Pathogenic/likely pathogenic
p.Ser1759Pro                       TAAD                                                                 Pathogenic/likely pathogenic
3q13.33-21.2 deletion        Developmental delay                                    Pathogenic/likely pathogenic
3q13.32-21.2 deletion        Developmental delay                                    Pathogenic/likely pathogenic
TAAD, thoracic aortic aneurysm and dissection.
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mutations.5 Although we do not have functional
data for the p.E1911V variant, the MYLK variants
reported by Wang et al. demonstrated an abnor-
mal kinase binding to calmodulin and reduced
kinase activity, thus providing a substrate for
acute aortic dissection with negligible or no aor-
tic enlargement prior to dissection.5 Loss-of-
function mutations resulting in decreased MLCK
product may result in decreased contractile abili-
ty of the smooth muscle cell.5 This is in part due
to the observed increased proteoglycan deposi-
tion in the aortic media, increased type III colla-
gen, and increased expression of the elastin-
degrading metalloproteinase, which have been
consistently reported to be overexpressed in
ascending aortic aneurysms.16 Because of the
need for future investigation on MYLK and its
role in FTAAD, we currently consider this gene to
be one of uncertain significance with regard to
causing FTAAD. The clinical significance of the
MYLK variant found in the proband and his
father is currently unclear. Although it is certain-
ly interesting that the father has this variant and
dilatation of the ascending aorta, we cannot, at
this time, determine if the two are associated.
Similarly, because this variant appears to be
paternally inherited in the proband, it is possible
the paternal grandfather with an abdominal
aneurysm also carried this variant. As noted pre-
viously, it is uncommon for an individual with
familial disease of the ascending aorta to have a
relative with isolated disease of the abdominal
aorta,1 but we cannot rule out a genetic predispo-
sition that, in addition to environmental factors,
was sufficient to cause his aneurysm. Genetic
testing of the grandfather was not discussed with
the family. The MYLK variant remains in our
opinion the most suggestive candidate. The fact
that the MYLK variant was not seen in 2500 sub-
jects of the 1000 Genomes Browser (http://brows-
er.1000genomes.org/index.html), in 6500 sub-
jects of the NHLBI Exome Sequencing Project
(ESP) database
(http://evs.gs.washington.edu/EVS/), or in 60,689
unrelated individuals of the Exome Aggregation
Consortium (ExAC) (Cambridge, MA,
http://exac.broadinstitute.org), which evaluated
exome data from individuals of European,
African American, Hispanic, Asian and other
backgrounds, is suggesting, yet not supporting,
its possible pathogenicity. Moreover, although
both SIFT and Polyphen2 software predictions
were concordant in defining the variant as dam-
aging, our cumulative damage score was low
(2/6). Despite the sensitivity of SIFT and
PolyPhen being quite high (69% and 68%,
respectively), their specificity is low (13% and
16%, respectively), and although they appear to
be reliable in predicting a deleterious effect in
loss-of-function variants,17 caution must be exer-
cised due to a possible overestimation of patho-
genicity. There are limitations to the genetic
testing that was performed on the proband. One
limitation to both the clinical and research test-
ing is that deletion/duplication analysis was not
performed. We therefore, cannot rule out a dele-
tion or duplication as the cause for the dissec-
tion. Of note, four genes have been added to the
clinical TAAD panel since the time the proband’s
testing was performed. One gene that has since
been added to the clinical panel that was not
included on our 246-gene research panel is the
SKI gene.
Variants of uncertain significance (VUS) are
often thought to be both difficult to interpret and
difficult to provide counseling over. In most situ-
ations, families who pursue genetic testing are
looking for an answer as to what caused the con-
dition in their family. A family or provider may
additionally be looking for an answer to help
determine appropriate surveillance moving for-
ward. When the result of the genetic test is a
VUS, it may make the determination of future
surveillance more complicated. In the case of
TAAD, guidelines have been set in place for sit-
uations in which a definitive genetic diagnosis
is not made. In the case presented here, without
an identified cause and without definitively
knowing from which side of the family a predis-
position may have been inherited, the proband’s
family was counseled and medical recommenda-
tions were provided in accordance to the
American College of Cardiology
Foundation/American Heart Association
Guidelines.3 Following the death of the proband,
all first-degree relatives underwent cardiac
imaging in the form of echocardiography. In this
family and other FTAAD families, given the
reduced penetrance and variable expressivity
present in FTAAD, it is recommended that first-
degree relatives have additional screening
approximately every two years.3
Despite the limitations of post mortem test-
ing, it is important to raise awareness of the
process and its availability following aortic dis-
section and rupture cases that tragically end in
death. The potential answers which may be
obtained through genetic analysis of the affect-
ed individual may be crucial in aiding assess-
ment of family members’ risks. Given that MYLK
is becoming increasingly common on clinical
TAAD genetic testing panels, we recognize the
need for further exploration of this gene in addi-
tion to the information that we have presented.
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